We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $4
Promising Clinical Trials and Strong Financial Position Bolster Buy Rating for SELLAS Life Sciences Group
SELLAS Life Sciences Gr Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate
Sellas Life Sciences | 8-K: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SELLAS Life Sciences 3Q Loss/Shr 10c >SLS